Drug profile

The FDA adverse-event record for Chlorphenamine

87 FDA reports name Chlorphenamine, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#835 of 2,679
by report volume (all drugs)
87
adverse-event reports
3.4%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Chlorphenamine ranks #834 of 2679 by total reports (87) and #887 of 1130 by death-coded share (3.4%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#834
This drug, reports of 2679
#887
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Chlorphenamine has 87 reports now versus 87 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Chlorphenamine changes

Signature read: Chlorphenamine's 3.4% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
87
Total Reports
3
Deaths Reported
3.4%
Death-coded share of reports

Active Ingredients

Chlorphenamine

Administration Routes

OralUnknown

Species Affected

Dog 75
Cat 12

Most Affected Breeds

Domestic Shorthair 9
Bichon Frise 6
Shih Tzu 5
Retriever - Labrador 5
Chihuahua 4
Spitz - German Pomeranian 4
Bulldog 3
Boxer (German Boxer) 3
Terrier - Yorkshire 3
Terrier - Jack Russell 2

Most Reported Reactions

Emesis 33
Vomiting 20
Lack of efficacy - NOS 10
Lethargy (see also Central nervous system depression in 'Neurological') 9
Behavioural disorder NOS 6
INEFFECTIVE, HEARTWORM LARVAE 3
Lack of efficacy (ectoparasite) - flea 3
Seizure NOS 3
Death 3
Other abnormal test result NOS 3
Elevated alanine aminotransferase (ALT) 3
Emesis (multiple) 3

Outcome Breakdown

Recovered/Normal
49 (56.3%)
Outcome Unknown
17 (19.5%)
Ongoing
11 (12.6%)
Recovered with Sequela
7 (8.0%)
Died
3 (3.4%)

Chlorphenamine: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Chlorphenamine, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Chlorphenamine (#835 of 2,679 by report volume); death-coded 3.4%. PlainBreed drug row · death-coded share stamp 3.4% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →